1 / 21

Update on CBER HIV-1 Subtype panel

Update on CBER HIV-1 Subtype panel. Indira Hewlett, Ph.D CBER/FDA. CBER HIV-1 subtype panel. 20 specimens representing subtypes A-G of group M, N and O 2 isolates of each subtype of group M, 1 of group N and 5 of group O Dilutions 10 4 , 10 3 , 10 2 per ml for all subtypes

meaghan-hamilton
Download Presentation

Update on CBER HIV-1 Subtype panel

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Update on CBER HIV-1 Subtype panel Indira Hewlett, Ph.D CBER/FDA

  2. CBER HIV-1 subtype panel • 20 specimens representing subtypes A-G of group M, N and O • 2 isolates of each subtype of group M, 1 of group N and 5 of group O • Dilutions 104, 103, 102 per ml for all subtypes • Samples tested by five manufacturers

  3. Virus isolates for HIV-1 subtype panel

  4. Prototype Panel Composition • Each panel was comprised of 2 isolates • Seven members including one negative control per panel; Panel O has nineteen members containing five distinct isolates and four negative controls. • Diluted to targeted ranges of Log 2 to Log 4 (copies/ml). • Tested by 5 different manufacturer’s assays

  5. Multi-lab testing

  6. Consensus Values of subtype panel samples

  7. Expected final formulation for panel • One isolate of each subtype representing subtypes A-G of group M, N and O • Four members including one negative control per panel • Diluted to targeted ranges of Log 2 to Log 4 (copies/ml).

  8. Summary • CBER has developed a well characterized panel for qualitative and quantitative detection of HIV-1 subtype RNA • Panel may be used 1) to establish LOD and 2) for lot release of HIV NAT assays for blood and plasma donor screening

  9. West Nile virus lot release and validation panel development

  10. Background The 2002 US outbreak of WNV identified transmission by Blood transfusion, Transplantation, Breast-feeding, Transplacental and Occupational by percutaneus injury During Aug 28, 2002-March 1, 2003, 61 possible Transfusion-Transmitted cases reported 21 confirmed from 14 blood donations 19 are not transfusion related, 21 inconclusive due to incomplete donor follow-up

  11. WNV testing • All reported cases of WNV transmission by blood transfusion have occurred during the acute, viremic phase • NAT may be the most appropriate strategy to interdict infectious donations • Virus titer in blood is low compared to other transmissible viruses (~1-5x103 copies/ml) and the viremia is transient. • Impact of pooling on sensitivity of WNV NAT assays is of concern

  12. Analytical sensitivity • FDA’s current standard for WNV NAT assays is 100 copies/ml for the individual donation • Standard may be revised as assay sensitivity improves and additional data on viremia and infectivity become available in future studies

  13. FDA Panel Development Efforts • Lot release panel for licensure and post-market surveillance of NAT tests • Qualification panel for evaluation of relative sensitivities of investigational NAT assays

  14. FDA NAT Panels • FDA NY99 and FDA-Hu2002 isolates characterized by genetic sequencing • Viral infectivity determination • PFU determined at both FDA and NY Dept. of Health Laboratories, and by cytopathic assays at FDA • RNA concentration measurements • Fluorescence and Optical density determination • TaqMan • Final panel specifications are being established through collaborative studies

  15. PFU Results on FDA Isolates • At FDA • NY99 (CDC Flamingo Isolate) 108/mL • HuWNV2002 108/mL • At NY State Dept. of Health • NY99 (CDC Flamingo Isolate) 5.5 x107/mL • HuWNV2002 9.5 x106/mL

  16. Quantitation of virus isolates: copies/mL

  17. Correlation between Copy/mL and PFU/mL

  18. FDA Plan for Qualification Panel • At least 100 pedigreed clinical specimens • RNA positive only • IgM positive only • Dual RNA and IgM positive • Panel will be evaluated in collaborative studies using various candidate NAT assays • Specifications for NAT panel will be established based on results of collaborative studies

  19. Summary • Both NY99 and FDA-Hu2002 stocks have a viral titer of 1010 copies/mL • PFU titers determined at NY State Dept of Health Laboratory and at FDA were three logs lower than copy numbers • Heat treatment of virus resulted in loss of infectivity and 2 to 3 log reduction in copy numbers as determined by TaqMan • Prototype panel is being formulated to evaluate performance of panel in a larger collaborative study

  20. Acknowledgements CBER • Owen Wood • Sherwin Lee Nelson Michael, DoD • Rolf Taffs Harvey Holmes, NIBSC • Jinjie Hu • Ana Machuca Robert Lanciotti, CDC • Maria Rios Laura Kramer, NYDOH

  21. Acknowledgements

More Related